ABT · 10-Q · 2026Q2 · Full report
Exact Sciences Acquisition
ABBOTT LABORATORIES · 2026-07-28 · Importance 94 · Surprise 100 · No source text
Abbott completed its acquisition of Exact Sciences on March 23, 2026, for approximately $20.6 billion, paying $105 per common share in cash. Abbott funded approximately $20.0 billion with long-term debt and the remainder with cash, while assuming approximately $2.8 billion of Exact Sciences debt that was nearly all repaid by June 30, 2026. The preliminary purchase-price allocation included $12.8 billion of acquired intangible assets, $11.4 billion of goodwill, $0.4 billion of net tangible assets, and $2.0 billion of deferred income taxes. Exact Sciences contributed approximately $1.0 billion of Abbott’s first-half 2026 sales and expanded the Diagnostic Products segment into cancer diagnostics through Cologuard, Oncotype DX, and Cancerguard.
Key facts
- Abbott completed the acquisition of Exact Sciences on March 23, 2026 for approximately $20.6 billion.
- The Exact Sciences acquisition was funded primarily through issuance of $20.0 billion of long-term debt in March 2026.
- Preliminary allocation of Exact Sciences purchase price: acquired intangible assets non-deductible $12.8 billion; goodwill non-deductible $11.4 billion; acquired net tangible assets $0.4 billion; deferred income taxes recorded at acquisition ($2.0) billion; net debt ($2.0) billion; total preliminary allocation $20.6 billion.
- The preliminary allocation of the Exact Sciences purchase price included $11.4 billion of goodwill (non-deductible).
- Unaudited pro forma consolidated net sales would have been approximately $12.6 billion and $24.5 billion for the three and six months ended June 30, 2026, respectively, after giving effect to the Exact Sciences acquisition.
- Abbott assumed approximately $2.8 billion of Exact Sciences' debt, nearly all of which was repaid as of June 30, 2026.
- From the acquisition date of March 23, 2026, Diagnostic Products results included approximately $1.0 billion of sales from Exact Sciences, which are reported as Cancer Diagnostics.
- The preliminary allocation of the Exact Sciences purchase price included $12.8 billion of acquired intangible assets (non-deductible).
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | +11.7% | The preliminary allocation of the Exact Sciences purchase price included $12.8 billion of acquired intangible assets (non-deductible). |
| revenue | positive | realized | +4.3% | Cancer Diagnostics sales were $1,015 million for the six months ended June 30, 2026 and were not present in the prior year (n/a). |
| revenue | positive | committed | +2.7% | Unaudited pro forma consolidated net sales would have been approximately $12.6 billion and $24.5 billion for the three and six months… |
| liability | negative | realized | -2.6% | Abbott assumed approximately $2.8 billion of Exact Sciences' debt, nearly all of which was repaid as of June 30, 2026. |
| liability | negative | realized | -1.8% | Preliminary allocation of Exact Sciences purchase price: acquired intangible assets non-deductible $12.8 billion; goodwill non-deductible… |
| liability | negative | contingent | — | The increase in contingent consideration from December 31, 2025 reflects contingent consideration assumed with the acquisition of Exact… |